Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

Topics in HIV medicine : a publication of the International AIDS Society, USA

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA.
PMID: 17016878
Top HIV Med. 2006 Aug-Sep;14(3):827-43.

CONTEXT: Guidelines for antiretroviral therapy are important for clinicians worldwide given the complexity of the field and the varied clinical situations in which these agents are used. The International AIDS Society-USA panel has updated its recommendations as warranted by...

Cite
Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006;14(3):827-43
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C., Fischl, M. A., Gazzard, B. G., Gatell, J. M., Hirsch, M. S., Katzenstein, D. A., Richman, D. D., Vella, S., Yeni, P. G., Volberding, P. A. (2006). Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Topics in HIV medicine : a publication of the International AIDS Society, USA, 14(3), 827-43.
Hammer, Scott M, et al. "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel." Topics in HIV medicine : a publication of the International AIDS Society, USA vol. 14,3 (2006): 827-43.
Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006 Aug-Sep;14(3):827-43. PMID: 17016878.
Copy Download .nbib Format: NLM
Bringing the end in sight: consensus regarding HIV screening strategies.

Annals of internal medicine

Das M, Volberding P.
PMID: 23698261
Ann Intern Med. 2013 Jul 02;159(1):63-4. doi: 10.7326/0003-4819-159-1-201307020-00643.

No abstract available.

Cite
Das M, Volberding P. Bringing the end in sight: consensus regarding HIV screening strategies. Ann Intern Med. 2013;159(1):63-4doi: 10.7326/0003-4819-159-1-201307020-00643.
Das, M., & Volberding, P. (2013). Bringing the end in sight: consensus regarding HIV screening strategies. Annals of internal medicine, 159(1), 63-4. https://doi.org/10.7326/0003-4819-159-1-201307020-00643
Das, Moupali, and Volberding, Paul. "Bringing the end in sight: consensus regarding HIV screening strategies." Annals of internal medicine vol. 159,1 (2013): 63-4. doi: https://doi.org/10.7326/0003-4819-159-1-201307020-00643
Das M, Volberding P. Bringing the end in sight: consensus regarding HIV screening strategies. Ann Intern Med. 2013 Jul 02;159(1):63-4. doi: 10.7326/0003-4819-159-1-201307020-00643. PMID: 23698261.
Copy Download .nbib Format: NLM
Suppressive neutrophils require PIM1 for metabolic fitness and survival during chronic viral infection.

Cell reports

Volberding PJ, Xin G, Kasmani MY, Khatun A, Brown AK, Nguyen C, Stancill JS, Martinez E, Corbett JA, Cui W.
PMID: 34038722
Cell Rep. 2021 May 25;35(8):109160. doi: 10.1016/j.celrep.2021.109160.

The immune response to a chronic viral infection is uniquely tailored to balance viral control and immunopathology. The role of myeloid cells in shaping the response to chronic viral infection, however, is poorly understood. We perform single-cell RNA sequencing...

Cite
Volberding PJ, Xin G, Kasmani MY, et al. Suppressive neutrophils require PIM1 for metabolic fitness and survival during chronic viral infection. Cell Rep. 2021;35(8):109160doi: 10.1016/j.celrep.2021.109160.
Volberding, P. J., Xin, G., Kasmani, M. Y., Khatun, A., Brown, A. K., Nguyen, C., Stancill, J. S., Martinez, E., Corbett, J. A., & Cui, W. (2021). Suppressive neutrophils require PIM1 for metabolic fitness and survival during chronic viral infection. Cell reports, 35(8), 109160. https://doi.org/10.1016/j.celrep.2021.109160
Volberding, Peter J, et al. "Suppressive neutrophils require PIM1 for metabolic fitness and survival during chronic viral infection." Cell reports vol. 35,8 (2021): 109160. doi: https://doi.org/10.1016/j.celrep.2021.109160
Volberding PJ, Xin G, Kasmani MY, Khatun A, Brown AK, Nguyen C, Stancill JS, Martinez E, Corbett JA, Cui W. Suppressive neutrophils require PIM1 for metabolic fitness and survival during chronic viral infection. Cell Rep. 2021 May 25;35(8):109160. doi: 10.1016/j.celrep.2021.109160. PMID: 34038722; PMCID: PMC8182757.
Copy Download .nbib Format: NLM
Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States.

Open forum infectious diseases

Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG.
PMID: 30931346
Open Forum Infect Dis. 2018 Dec 26;6(1):ofy353. doi: 10.1093/ofid/ofy353. eCollection 2019 Jan.

BACKGROUND: Two million individuals with chronic hepatitis B (CHB) in the United States are at risk for premature death due to liver cancer and cirrhosis. CHB can be prevented by vaccination and controlled with treatment.METHODS: We created a lifetime...

Cite
Chahal HS, Peters MG, Harris AM, et al. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open Forum Infect Dis. 2018;6(1):ofy353doi: 10.1093/ofid/ofy353.
Chahal, H. S., Peters, M. G., Harris, A. M., McCabe, D., Volberding, P., & Kahn, J. G. (2019). Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open forum infectious diseases, 6(1), ofy353. https://doi.org/10.1093/ofid/ofy353
Chahal, Harinder S, et al. "Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States." Open forum infectious diseases vol. 6,1 (2019): ofy353. doi: https://doi.org/10.1093/ofid/ofy353
Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open Forum Infect Dis. 2018 Dec 26;6(1):ofy353. doi: 10.1093/ofid/ofy353. eCollection 2019 Jan. PMID: 30931346; PMCID: PMC6346293.
Copy Download .nbib Format: NLM
Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects.

iScience

Cheng G, Hardy M, Topchyan P, Zander R, Volberding P, Cui W, Kalyanaraman B.
PMID: 34189437
iScience. 2021 May 31;24(6):102673. doi: 10.1016/j.isci.2021.102673. eCollection 2021 Jun 25.

Hydroxyurea (HU), an FDA-approved drug for treating sickle cell disease, is used as an antitumor drug alone and together with conventional chemotherapeutics or radiation therapy. HU is used primarily to treat myeloproliferative diseases because it inhibits the enzyme ribonucleotide...

Cite
Cheng G, Hardy M, Topchyan P, et al. Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects. iScience. 2021;24(6):102673doi: 10.1016/j.isci.2021.102673.
Cheng, G., Hardy, M., Topchyan, P., Zander, R., Volberding, P., Cui, W., & Kalyanaraman, B. (2021). Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects. iScience, 24(6), 102673. https://doi.org/10.1016/j.isci.2021.102673
Cheng, Gang, et al. "Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects." iScience vol. 24,6 (2021): 102673. doi: https://doi.org/10.1016/j.isci.2021.102673
Cheng G, Hardy M, Topchyan P, Zander R, Volberding P, Cui W, Kalyanaraman B. Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects. iScience. 2021 May 31;24(6):102673. doi: 10.1016/j.isci.2021.102673. eCollection 2021 Jun 25. PMID: 34189437; PMCID: PMC8215227.
Copy Download .nbib Format: NLM
Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion.

Open forum infectious diseases

Chu CE, Wu F, He X, Zhou K, Cheng Y, Cai W, Geng E, Volberding P, Tucker JD.
PMID: 27419150
Open Forum Infect Dis. 2016 Jun 24;3(2):ofw065. doi: 10.1093/ofid/ofw065. eCollection 2016 Apr.

Background.  Hepatitis C virus (HCV) treatment access among human immunodeficiency virus (HIV)/HCV-coinfected people who inject drugs is poor, despite a high burden of disease in this population. Understanding barriers and facilitators to HCV treatment uptake is critical to the...

Cite
Chu CE, Wu F, He X, et al. Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion. Open Forum Infect Dis. 2016;3(2):ofw065doi: 10.1093/ofid/ofw065.
Chu, C. E., Wu, F., He, X., Zhou, K., Cheng, Y., Cai, W., Geng, E., Volberding, P., & Tucker, J. D. (2016). Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion. Open forum infectious diseases, 3(2), ofw065. https://doi.org/10.1093/ofid/ofw065
Chu, Carissa E, et al. "Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion." Open forum infectious diseases vol. 3,2 (2016): ofw065. doi: https://doi.org/10.1093/ofid/ofw065
Chu CE, Wu F, He X, Zhou K, Cheng Y, Cai W, Geng E, Volberding P, Tucker JD. Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion. Open Forum Infect Dis. 2016 Jun 24;3(2):ofw065. doi: 10.1093/ofid/ofw065. eCollection 2016 Apr. PMID: 27419150; PMCID: PMC4943171.
Copy Download .nbib Format: NLM
Health impact of human rights testimony: harming the most vulnerable?.

BMJ global health

Meffert SM, Shome S, Neylan TC, Musalo K, Fineberg HV, Cooke MM, Volberding PA, Goosby EP.
PMID: 28588904
BMJ Glob Health. 2016 Jul 21;1(1):e000001. doi: 10.1136/bmjgh-2015-000001. eCollection 2016.

BACKGROUND: Current legal efforts to document human rights violations typically include interviews in which survivors are asked to provide detailed descriptions of their traumatic experiences during a single meeting. Research on similar interview techniques used as part of a...

Cite
Meffert SM, Shome S, Neylan TC, et al. Health impact of human rights testimony: harming the most vulnerable?. BMJ Glob Health. 2016;1(1):e000001doi: 10.1136/bmjgh-2015-000001.
Meffert, S. M., Shome, S., Neylan, T. C., Musalo, K., Fineberg, H. V., Cooke, M. M., Volberding, P. A., & Goosby, E. P. (2016). Health impact of human rights testimony: harming the most vulnerable?. BMJ global health, 1(1), e000001. https://doi.org/10.1136/bmjgh-2015-000001
Meffert, Susan M, et al. "Health impact of human rights testimony: harming the most vulnerable?." BMJ global health vol. 1,1 (2016): e000001. doi: https://doi.org/10.1136/bmjgh-2015-000001
Meffert SM, Shome S, Neylan TC, Musalo K, Fineberg HV, Cooke MM, Volberding PA, Goosby EP. Health impact of human rights testimony: harming the most vulnerable?. BMJ Glob Health. 2016 Jul 21;1(1):e000001. doi: 10.1136/bmjgh-2015-000001. eCollection 2016. PMID: 28588904; PMCID: PMC5321303.
Copy Download .nbib Format: NLM
HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel.

Topics in antiviral medicine

Volberding PA.
PMID: 28402930
Top Antivir Med. 2017 Feb/Mar;25(1):17-24.

Updated recommendations from the IAS-USA Antiretroviral Guidelines Panel on antiretroviral therapy for the treatment and prevention of HIV infection in adults were published in the Journal of the American Medical Association in 2016. The updated, evidence-based recommendations address when...

Cite
Volberding PA. HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel. Top Antivir Med. 2017;25(1):17-24
Volberding, P. A. (2017). HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel. Topics in antiviral medicine, 25(1), 17-24.
Volberding, Paul A. "HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel." Topics in antiviral medicine vol. 25,1 (2017): 17-24.
Volberding PA. HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel. Top Antivir Med. 2017 Feb/Mar;25(1):17-24. PMID: 28402930; PMCID: PMC5677040.
Copy Download .nbib Format: NLM
ACUTE OUTCOMES OF MYOFASCIAL DECOMPRESSION (CUPPING THERAPY) COMPARED TO SELF-MYOFASCIAL RELEASE ON HAMSTRING PATHOLOGY AFTER A SINGLE TREATMENT.

International journal of sports physical therapy

Warren AJ, LaCross Z, Volberding JL, O'Brien MS.
PMID: 33354391
Int J Sports Phys Ther. 2020 Aug;15(4):579-592.

BACKGROUND: Myofascial decompression (MFD), or cupping, and self-myofascial release (SMR) are common techniques utilized to treat soft tissue injuries and increase flexibility. MFD is a negative pressure soft tissue treatment technique using suction to manipulate the skin and underlying...

Cite
Warren AJ, LaCross Z, Volberding JL, et al. ACUTE OUTCOMES OF MYOFASCIAL DECOMPRESSION (CUPPING THERAPY) COMPARED TO SELF-MYOFASCIAL RELEASE ON HAMSTRING PATHOLOGY AFTER A SINGLE TREATMENT. Int J Sports Phys Ther. 2020;15(4):579-592
Warren, A. J., LaCross, Z., Volberding, J. L., & O'Brien, M. S. (2020). ACUTE OUTCOMES OF MYOFASCIAL DECOMPRESSION (CUPPING THERAPY) COMPARED TO SELF-MYOFASCIAL RELEASE ON HAMSTRING PATHOLOGY AFTER A SINGLE TREATMENT. International journal of sports physical therapy, 15(4), 579-592.
Warren, Aric J, et al. "ACUTE OUTCOMES OF MYOFASCIAL DECOMPRESSION (CUPPING THERAPY) COMPARED TO SELF-MYOFASCIAL RELEASE ON HAMSTRING PATHOLOGY AFTER A SINGLE TREATMENT." International journal of sports physical therapy vol. 15,4 (2020): 579-592.
Warren AJ, LaCross Z, Volberding JL, O'Brien MS. ACUTE OUTCOMES OF MYOFASCIAL DECOMPRESSION (CUPPING THERAPY) COMPARED TO SELF-MYOFASCIAL RELEASE ON HAMSTRING PATHOLOGY AFTER A SINGLE TREATMENT. Int J Sports Phys Ther. 2020 Aug;15(4):579-592. PMID: 33354391; PMCID: PMC7735689.
Copy Download .nbib Format: NLM
Antiretroviral therapy and management of HIV infection.

Lancet (London, England)

Volberding PA, Deeks SG.
PMID: 20609987
Lancet. 2010 Jul 03;376(9734):49-62. doi: 10.1016/S0140-6736(10)60676-9.

Antiretroviral therapy of HIV infection has changed a uniformly fatal into a potentially chronic disease. There are now 17 drugs in common use for HIV treatment. Patients who can access and adhere to combination therapy should be able to...

Cite
Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376(9734):49-62doi: 10.1016/S0140-6736(10)60676-9.
Volberding, P. A., & Deeks, S. G. (2010). Antiretroviral therapy and management of HIV infection. Lancet (London, England), 376(9734), 49-62. https://doi.org/10.1016/S0140-6736(10)60676-9
Volberding, Paul A, and Deeks, Steven G. "Antiretroviral therapy and management of HIV infection." Lancet (London, England) vol. 376,9734 (2010): 49-62. doi: https://doi.org/10.1016/S0140-6736(10)60676-9
Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010 Jul 03;376(9734):49-62. doi: 10.1016/S0140-6736(10)60676-9. PMID: 20609987.
Copy Download .nbib Format: NLM
Procalcitonin Perplexity - Prolonged Idiopathic Elevation in Pleomorphic Sarcoma: A Case Report and Review of the Literature.

Cureus

Arce Gastelum A, Volberding T, Freeman SC, Dick M, Gbadamosi-Akindele M.
PMID: 32582476
Cureus. 2020 May 20;12(5):e8215. doi: 10.7759/cureus.8215.

Historically, elevations in procalcitonin (PCT) have been implicated in medullary thyroid cancer and neuroendocrine tumors. More recently, the trending of PCT has been suggested as a monitor of infection to assess the presence, clearance and eradication of infection, especially...

Cite
Arce Gastelum A, Volberding T, Freeman SC, et al. Procalcitonin Perplexity - Prolonged Idiopathic Elevation in Pleomorphic Sarcoma: A Case Report and Review of the Literature. Cureus. 2020;12(5):e8215doi: 10.7759/cureus.8215.
Arce Gastelum, A., Volberding, T., Freeman, S. C., Dick, M., & Gbadamosi-Akindele, M. (2020). Procalcitonin Perplexity - Prolonged Idiopathic Elevation in Pleomorphic Sarcoma: A Case Report and Review of the Literature. Cureus, 12(5), e8215. https://doi.org/10.7759/cureus.8215
Arce Gastelum, Alheli, et al. "Procalcitonin Perplexity - Prolonged Idiopathic Elevation in Pleomorphic Sarcoma: A Case Report and Review of the Literature." Cureus vol. 12,5 (2020): e8215. doi: https://doi.org/10.7759/cureus.8215
Arce Gastelum A, Volberding T, Freeman SC, Dick M, Gbadamosi-Akindele M. Procalcitonin Perplexity - Prolonged Idiopathic Elevation in Pleomorphic Sarcoma: A Case Report and Review of the Literature. Cureus. 2020 May 20;12(5):e8215. doi: 10.7759/cureus.8215. PMID: 32582476; PMCID: PMC7306675.
Copy Download .nbib Format: NLM
Suppressive neutrophils require PIM1 for metabolic fitness and survival during chronic viral infection.

Cell reports

Volberding PJ, Xin G, Kasmani MY, Khatun A, Brown AK, Nguyen C, Stancill JS, Martinez E, Corbett JA, Cui W.
PMID: 34038722
Cell Rep. 2021 May 25;35(8):109160. doi: 10.1016/j.celrep.2021.109160.

The immune response to a chronic viral infection is uniquely tailored to balance viral control and immunopathology. The role of myeloid cells in shaping the response to chronic viral infection, however, is poorly understood. We perform single-cell RNA sequencing...

Cite
Volberding PJ, Xin G, Kasmani MY, et al. Suppressive neutrophils require PIM1 for metabolic fitness and survival during chronic viral infection. Cell Rep. 2021;35(8):109160doi: 10.1016/j.celrep.2021.109160.
Volberding, P. J., Xin, G., Kasmani, M. Y., Khatun, A., Brown, A. K., Nguyen, C., Stancill, J. S., Martinez, E., Corbett, J. A., & Cui, W. (2021). Suppressive neutrophils require PIM1 for metabolic fitness and survival during chronic viral infection. Cell reports, 35(8), 109160. https://doi.org/10.1016/j.celrep.2021.109160
Volberding, Peter J, et al. "Suppressive neutrophils require PIM1 for metabolic fitness and survival during chronic viral infection." Cell reports vol. 35,8 (2021): 109160. doi: https://doi.org/10.1016/j.celrep.2021.109160
Volberding PJ, Xin G, Kasmani MY, Khatun A, Brown AK, Nguyen C, Stancill JS, Martinez E, Corbett JA, Cui W. Suppressive neutrophils require PIM1 for metabolic fitness and survival during chronic viral infection. Cell Rep. 2021 May 25;35(8):109160. doi: 10.1016/j.celrep.2021.109160. PMID: 34038722; PMCID: PMC8182757.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries